Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 6/2002

01-06-2002

Daily Norfloxacin Is More Effective Than Weekly Rufloxacin in Prevention of Spontaneous Bacterial Peritonitis Recurrence

Authors: Tilman M. Bauer, Antonio Follo, Miguel Navasa, Jordi Vila, Ramon Planas, Gerardo Clemente, Victor Vargas, Felipe Bory, Pere Vaquer, Juan Rodés

Published in: Digestive Diseases and Sciences | Issue 6/2002

Login to get access
Metadata
Title
Daily Norfloxacin Is More Effective Than Weekly Rufloxacin in Prevention of Spontaneous Bacterial Peritonitis Recurrence
Authors
Tilman M. Bauer
Antonio Follo
Miguel Navasa
Jordi Vila
Ramon Planas
Gerardo Clemente
Victor Vargas
Felipe Bory
Pere Vaquer
Juan Rodés
Publication date
01-06-2002
Publisher
Kluwer Academic Publishers-Plenum Publishers
Published in
Digestive Diseases and Sciences / Issue 6/2002
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1023/A:1015386901343

Other articles of this Issue 6/2002

Digestive Diseases and Sciences 6/2002 Go to the issue

OriginalPaper

CASE REPORT: Chronic Hepatitis C and Autoimmune Cholangitis: A Case Study and Literature Review

OriginalPaper

Short-Term Intestinal Ischemia–Reperfusion Alters Intestinal Motility That Can Be Preserved by Xanthine Oxidase Inhibition

OriginalPaper

Analysis of Sequence Configurations of the ISDR, PKR-Binding Domain, and V3 Region as Predictors of Response to Induction Interferon-α and Ribavirin Therapy in Chronic Hepatitis C Infection

Announcement

News and Notices

OriginalPaper

Group Counseling Psychotherapy for Patients with Functional Gastrointestinal Disorders: Development of New Measures for Symptom Severity and Quality of Life

OriginalPaper

Up-Regulation of CD11a (LFA-1) Expression on Peripheral CD4+ T Cells in Primary Biliary Cirrhosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits